Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan

Embecta将停止胰岛素贴片泵项目并启动组织重组计划

Benzinga · 2024/11/26 19:33

The Company currently expects to incur total pre-tax charges of between $35 million and $45 million in fiscal year 2025 related to the restructuring plan, consisting of between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of the patch pump program, and between $10 million and $15 million in pre-tax, non-cash charges for asset impairments and write-offs. Note, these preliminary estimates may be revised following the completion of the ongoing analysis of the expected additional pre-tax non-cash charges associated with the implementation of the restructuring plan.
The Company expects the restructuring plan to be substantially complete during the first half of fiscal year 2025 and expects the discontinuation of the patch pump program and organizational restructuring plan to generate annualized pre-tax cost savings of between $60 million and $65 million. Given the organizational restructuring plan, the Company has decided to postpone the previously announced Analyst & Investor Day to Spring 2025.

该公司目前预计，2025财年与重组计划相关的税前费用总额在3500万至4,500万美元之间，其中包括2500万至3000万美元的税前费用、计划裁员的现金费用和其他因补丁泵计划终止而产生的相关成本，以及1000万至1500万美元的资产减值和注销的税前非现金费用。请注意，在完成对与实施重组计划相关的预期额外税前非现金费用的分析后，这些初步估计可能会进行修订。
该公司预计，重组计划将在2025财年上半年基本完成，并预计补丁泵计划和组织重组计划的终止将每年节省6000万至6500万美元的税前成本。鉴于组织重组计划，公司决定将先前宣布的分析师和投资者日推迟到2025年春季。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

风险及免责提示